Summary

Eligibility
for people ages 3-17 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion

Description

Summary

A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Pitt Hopkins Syndrome.

Official Title

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)

Details

The primary purpose of this study is to investigate the safety, tolerability and pharmacokinetics of treatment with NNZ-2591 oral solution in children and adolescents with Pitt Hopkins Syndrome. The secondary purpose is to investigate measures of efficacy. Subjects will receive treatment with NNZ-2591 oral solution (50 mg/mL) at weight-banded doses for a total of 13 weeks.

Keywords

Pitt Hopkins Syndrome Hyperventilation Intellectual Disability Syndrome Facies NNZ-2591

Eligibility

You can join if…

Open to people ages 3-17

  1. Clinical diagnosis of PTHS with a documented disease-causing genetic etiology for the disorder.
  2. Males or females aged 3-17 years.
  3. Subjects with a Clinical Global Impression- Severity (CGI-S) score of 4 or greater at the Screening visit.
  4. Each subject must be able to swallow the study medication provided as a liquid solution.
  5. Caregiver(s) must have sufficient English language skills.

You CAN'T join if...

  1. Clinically significant abnormalities in safety laboratory tests at Screening.
  2. Abnormal QTcF interval or prolongation at Screening.
  3. Any other clinically significant finding (as determined by the Investigator) on ECG at the Screening visit.
  4. Excluded concomitant treatments.
  5. Actively undergoing regression or loss of skills.
  6. Unstable seizure profile.
  7. Current clinically significant cardiovascular, renal, hepatic, gastrointestinal, respiratory, endocrine disease, or clinically significant organ impairment. This is determined by the Investigator at Screening.
  8. Current clinically significant hypo- or hyperthyroidism. Type 1 or Type 2 diabetes mellitus requiring insulin (whether well controlled or uncontrolled), or uncontrolled Type 1 or Type 2 diabetes.
  9. Has planned surgery during the study.
  10. . History of, or current, cerebrovascular disease or brain trauma.
  11. . History of, or current catatonia or catatonia-like symptoms.
  12. . History of, or current, malignancy.
  13. . Current major or persistent depressive disorder (including bipolar depression).
  14. . Significant, uncorrected visual or uncorrected hearing impairment.
  15. . Allergy to strawberry.

Locations

  • University of California at San Francisco
    San Francisco California 94143 United States
  • Children's Hospital Colorado
    Aurora Colorado 80045 United States

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Neuren Pharmaceuticals Limited
ID
NCT05025332
Phase
Phase 2
Study Type
Interventional
Last Updated